In the aggressively growing AML model, i.v. administration of mixed (1:1) human type 1 NKT/Vγ9Vδ2-T cells at day 0 and 7 had a modest effect on survival, which was significantly prolonged in combination with twice-weekly i.v. administration of CD1d-Vδ2 bsTCE (median survival of 14, 16, and 19 days, respectively) (Figure 6A). The gene discussed is CD1D; the disease is acute myeloid leukemia.